Towards developing biomarkers for glioblastoma multiforme: a proteomics view

No abstract is available for this paper.

• Publication year

  2014

• Venue

  Espert Review of Proteomics

• Publication date

  2014-09-16

• Fields of study

  Biology, Medicine

• Identifiers
  DOI 10.1586/14789450.2014.939634PMID 25115191
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Discovery and saturation analysis of cancer genes across 21 tumor types

  2014cited by this paper
• The search for novel therapeutic strategies in the treatment of recurrent glioblastoma multiforme

  2014cited by this paper
• Identification of plasma biomarker candidates in glioblastoma using an antibody-array-based proteomic approach

  2014cited by this paper
• Detecting cancer by monitoring circulating tumor DNA

  2014cited by this paper
• The combination of IDH1 mutations and MGMT methylation status predicts survival in glioblastoma better than either IDH1 or MGMT alone.

  2014cited by this paper
• Clinical Proteomics in Cancer Research

  2013cited by this paper
• Intratumor heterogeneity in human glioblastoma reflects cancer evolutionary dynamics

  2013cited by this paper
• Targeting protein-protein interactions as an anticancer strategy.

  2013cited by this paper
• NADP+ -dependent IDH1 R132 mutation and its relevance for glioma patient survival.

  2013influential reference
• Isocitrate dehydrogenase 1 (IDH1) mutation-specific microRNA signature predicts favorable prognosis in glioblastoma patients with IDH1 wild type

  2013cited by this paper
• Detection of EGFRvIII mutant DNA in the peripheral blood of brain tumor patients

  2013influential reference
• Secretome analysis of Glioblastoma cell line--HNGC-2.

  2013influential reference
• Significance of complete 1p/19q co-deletion, IDH1 mutation and MGMT promoter methylation in gliomas: use with caution

  2013cited by this paper
• Heterogeneous nuclear ribonucleoproteins and their interactors are a major class of deregulated proteins in anaplastic astrocytoma: a grade III malignant glioma.

  2013cited by this paper
• Circulating biomarkers of CNS tumors: an update.

  2013cited by this paper
• SILAC‐based quantitative proteomic analysis of gastric cancer secretome

  2013cited by this paper
• Prognostic or predictive value of MGMT promoter methylation in gliomas depends on IDH1 mutation

  2013cited by this paper
• The epidermal growth factor receptor variant III (EGFRvIII): where wild things are altered

  2013cited by this paper
• Molecular neuro-oncology in clinical practice: a new horizon.

  2013cited by this paper
• Sieving through the cancer secretome.

  2013cited by this paper
• The somatic genomic landscape of glioblastoma.

  2013influential reference
• Exosomes reflect the hypoxic status of glioma cells and mediate hypoxia-dependent activation of vascular cells during tumor development

  2013cited by this paper
• ExoCarta as a resource for exosomal research

  2012cited by this paper
• The disturbed blood-brain barrier in human glioblastoma.

  2012cited by this paper
• Glioblastoma, a Brief Review of History, Molecular Genetics, Animal Models and Novel Therapeutic Strategies

  2012cited by this paper
• Detection of IDH1 mutation in the plasma of patients with glioma

  2012cited by this paper
• LC-MS/MS Analysis of Differentially Expressed Glioblastoma Membrane Proteome Reveals Altered Calcium Signaling and Other Protein Groups of Regulatory Functions*

  2012influential reference
• Current Progress on Understanding MicroRNAs in Glioblastoma Multiforme.

  2012cited by this paper
• Investigation of serum proteome alterations in human glioblastoma multiforme

  2012cited by this paper
• Effective enrichment of cholangiocarcinoma secretomes using the hollow fiber bioreactor culture system.

  2012cited by this paper
• G-protein coupled receptor-associated sorting protein 1 (GASP-1), a ubiquitous tumor marker.

  2012cited by this paper
• A Systematic Review of MicroRNA in Glioblastoma Multiforme: Micro-modulators in the Mesenchymal Mode of Migration and Invasion

  2012cited by this paper
• Glioblastoma—a moving target

  2012cited by this paper
• Proteins with Altered Levels in Plasma from Glioblastoma Patients as Revealed by iTRAQ-Based Quantitative Proteomic Analysis

  2012cited by this paper
• Role of microRNAs in gliomagenesis: targeting miRNAs in glioblastoma multiforme therapy

  2012cited by this paper
• Secreted proteins as a fundamental source for biomarker discovery

  2012cited by this paper
• Phosphoproteome of Human Glioblastoma Initiating Cells Reveals Novel Signaling Regulators Encoded by the Transcriptome

  2012cited by this paper
• MGMT gene promoter methylation as a potent prognostic factor in glioblastoma treated with temozolomide-based chemoradiotherapy: a single-institution study.

  2012cited by this paper
• Protein typing of circulating microvesicles allows real-time monitoring of glioblastoma therapy

  2012cited by this paper
• EGFRvIII promotes glioma angiogenesis and growth through the NF-κB, interleukin-8 pathway

  2012cited by this paper
• Proteomic Analysis of Exosomes from Mutant KRAS Colon Cancer Cells Identifies Intercellular Transfer of Mutant KRAS*

  2012cited by this paper
• Analysis of exosome release and its prognostic value in human colorectal cancer

  2012cited by this paper
• Circulating MicroRNAs as Minimally Invasive Biomarkers for Cancer Theragnosis and Prognosis

  2011cited by this paper
• Glioblastoma cell secretome: analysis of three glioblastoma cell lines reveal 148 non-redundant proteins.

  2011cited by this paper
• Prognostic significance of IDH-1 and MGMT in patients with glioblastoma: One step forward, and one step back?

  2011cited by this paper
• Mosaic amplification of multiple receptor tyrosine kinase genes in glioblastoma.

  2011cited by this paper
• A Ten-microRNA Expression Signature Predicts Survival in Glioblastoma

  2011cited by this paper
• Proteomics of gliomas: initial biomarker discovery and evolution of technology.

  2011cited by this paper
• Circulating markers of angiogenesis, inflammation, and coagulation in patients with glioblastoma

  2011cited by this paper
• Integration and analysis of genome-scale data from gliomas

  2011cited by this paper
• Serum angiogenic profile of patients with glioblastoma identifies distinct tumor subtypes and shows that TIMP-1 is a prognostic factor.

  2011cited by this paper
• Glioblastoma microvesicles transport RNA and proteins that promote tumour growth and provide diagnostic biomarkers

  2011cited by this paper
• MicroRNAs and glioblastoma: roles in core signalling pathways and potential clinical implications

  2011cited by this paper
• Secretome signature of invasive glioblastoma multiforme.

  2011cited by this paper
• Integrated genomic analysis identifies clinically relevant subtypes of glioblastoma.

  2010cited by this paper
• MicroRNAs: potential biomarkers for cancer diagnosis, prognosis and targets for therapy.

  2010cited by this paper
• Glioma proteomics: status and perspectives.

  2010cited by this paper
• Establishing the Proteome of Normal Human Cerebrospinal Fluid

  2010cited by this paper
• Proteomic identification of haptoglobin α2 as a glioblastoma serum biomarker: implications in cancer cell migration and tumor growth.

  2010cited by this paper
• NetPath: a public resource of curated signal transduction pathways

  2010cited by this paper
• The Proneural Molecular Signature Is Enriched in Oligodendrogliomas and Predicts Improved Survival among Diffuse Gliomas

  2010cited by this paper
• Characterization of R132H Mutation‐specific IDH1 Antibody Binding in Brain Tumors

  2010cited by this paper
• Integrated analysis of mutations, miRNA and mRNA expression in glioblastoma

  2010cited by this paper
• Basic design of MRM assays for peptide quantification.

  2010cited by this paper
• Integrated genomic analysis identifies clinically relevant subtypes of glioblastoma characterized by abnormalities in PDGFRA, IDH1, EGFR, and NF1.

  2010influential reference
• Peptide screening of cerebrospinal fluid in patients with glioblastoma multiforme.

  2010cited by this paper
• Identification of Potential Serum Biomarkers of Glioblastoma: Serum Osteopontin Levels Correlate with Poor Prognosis

  2010cited by this paper
• Identification of diagnostic serum protein profiles of glioblastoma patients

  2010cited by this paper
• Serum Angiogenic Profile of Patients with Glioblastoma Identifies Distinct Tumor Subtypes and Shows That TIMP-1 Is a Prognostic Factor

  2010cited by this paper
• Glioma Pathophysiology: Insights Emerging from Proteomics

  2010cited by this paper
• Serum proteomics of glioma: methods and applications

  2009cited by this paper
• IDH1 mutations are present in the majority of common adult gliomas but rare in primary glioblastomas.

  2009cited by this paper
• Proteomic study of human glioblastoma multiforme tissue employing complementary two-dimensional liquid chromatography- and mass spectrometry-based approaches.

  2009cited by this paper
• Plasma IGFBP-2 levels predict clinical outcomes of patients with high-grade gliomas.

  2009cited by this paper
• Novel anti‐filamin‐A antibody detects a secreted variant of filamin‐A in plasma from patients with breast carcinoma and high‐grade astrocytoma

  2009cited by this paper
• Proteomics Analysis of A33 Immunoaffinity-purified Exosomes Released from the Human Colon Tumor Cell Line LIM1215 Reveals a Tissue-specific Protein Signature*

  2009cited by this paper
• Proteomics of tumor‐specific proteins in cerebrospinal fluid of patients with astrocytoma: Usefulness of gelsolin protein

  2009cited by this paper
• IDH1 Mutations as Molecular Signature and Predictive Factor of Secondary Glioblastomas

  2009cited by this paper
• High serum level of plasminogen activator inhibitor-1 predicts histological grade of intracerebral gliomas.

  2008cited by this paper
• Glioblastoma microvesicles transport RNA and protein that promote tumor growth and provide diagnostic biomarkers

  2008cited by this paper
• A role for glutamate in growth and invasion of primary brain tumors

  2008cited by this paper
• Comprehensive genomic characterization defines human glioblastoma genes and core pathways

  2008cited by this paper
• The tumor microenvironment and its role in promoting tumor growth

  2008cited by this paper
• PBEF1/NAmPRTase/Visfatin: A potential malignant astrocytoma/glioblastoma serum marker with prognostic value

  2008cited by this paper
• Serum alpha 2-HS glycoprotein predicts survival in patients with glioblastoma.

  2008cited by this paper
• Integrated analysis of the cerebrospinal fluid peptidome and proteome.

  2008cited by this paper
• Serum GFAP is a diagnostic marker for glioblastoma multiforme.

  2007cited by this paper
• Proteomic identification of biomarkers in the cerebrospinal fluid (CSF) of astrocytoma patients.

  2007cited by this paper
• Biomarker discovery: A proteomic approach for brain cancer profiling

  2007cited by this paper
• Malignant astrocytic glioma: genetics, biology, and paths to treatment.

  2007cited by this paper
• Alteration of serum and tumoral neural cell adhesion molecule (NCAM) isoforms in patients with brain tumors

  2007cited by this paper
• Epidermal Growth Factor Receptor Serum Levels and Prognostic Value in Malignant Gliomas

  2007cited by this paper
• Differential Protein Expression, Protein Profiles of Human Gliomas, and Clinical Implications

  2007cited by this paper
• Serum IgE, tumor epidermal growth factor receptor expression, and inherited polymorphisms associated with glioma survival.

  2006cited by this paper
• The blood peptidome: a higher dimension of information content for cancer biomarker discovery

  2006cited by this paper
• APRIL is increased in serum of patients with brain glioblastoma multiforme.

  2006cited by this paper
• Marked genomic differences characterize primary and secondary glioblastoma subtypes and identify two distinct molecular and clinical secondary glioblastoma entities.

  2006cited by this paper
• Molecular subclasses of high-grade glioma predict prognosis, delineate a pattern of disease progression, and resemble stages in neurogenesis.

  2006cited by this paper
• The amplified peptidome: the new treasure chest of candidate biomarkers.

  2006cited by this paper
• YKL-40 and Matrix Metalloproteinase-9 as Potential Serum Biomarkers for Patients with High-Grade Gliomas

  2006cited by this paper

• Monitoring Cerebrospinal Fluid Inflammatory Mediators by Olink Target 48 Cytokine Panel.

  2025cites this paper
• An interview with William Cho

  2025cites this paper
• Recent advances in the detection of glioblastoma, from imaging-based methods to proteomics and biosensors: A narrative review

  2023cites this paper
• Investigating the Potential of Lipids for Use as Biomarkers for Glioblastoma via an Untargeted Lipidomics Approach

  2022cites this paper
• The Big Picture of Glioblastoma Malignancy: A Meta-Analysis of Glioblastoma Proteomics to Identify Altered Biological Pathways

  2021cites this paper
• Plasma-Derived Extracellular Vesicles Reveal Galectin-3 Binding Protein as Potential Biomarker for Early Detection of Glioma

  2021cites this paper
• The development and clinical applications of proteomics: an Indian perspective

  2020cites this paper
• Glioblastoma CUSA Fluid Protein Profiling: A Comparative Investigation of the Core and Peripheral Tumor Zones

  2020cites this paper
• Promising RNA-based cancer gene therapy using extracellular vesicles for drug delivery

  2020cites this paper
• Altered transcriptional regulatory proteins in glioblastoma and YBX1 as a potential regulator of tumor invasion

  2019cites this paper
• The applications of big data in molecular diagnostics

  2019cites this paper
• Exosomes regulate neurogenesis and circuit assembly

  2019cites this paper
• Machine‐learning based radiogenomics analysis of MRI features and metagenes in glioblastoma multiforme patients with different survival time

  2019cites this paper
• Single-Cell Omics in Personalized Medicine

  2019cites this paper
• Monitoring the Cerebrospinal Fluid Cytokine Profile Using Membrane-Based Antibody Arrays.

  2019cites this paper
• Pediatric brain tumors: Update of proteome-based studies.

  2018cites this paper
• Identification of blood biomarkers in glioblastoma by SWATH mass spectrometry and quantitative targeted absolute proteomics

  2018cites this paper
• The Impact of Oncogenic EGFRvIII on the Proteome of Extracellular Vesicles Released from Glioblastoma Cells*

  2018cites this paper
• Predicting Glioblastoma Response to Bevacizumab Through MRI Biomarkers of the Tumor Microenvironment

  2018cites this paper
• Integration of Transcriptomic and Proteomic Data for Disease Insights

  2017cites this paper
• Identifying survival-associated modules from the dysregulated triplet network in glioblastoma multiforme

  2017cites this paper
• Cyclophilin A was revealed as a candidate marker for human oral submucous fibrosis by proteomic analysis

  2017cites this paper
• Exosomes regulate Neurogenesis and Circuit Assembly in a Model of Rett Syndrome

  2017cites this paper
• Multi-Omics Data Integration and Mapping of Altered Kinases to Pathways Reveal Gonadotropin Hormone Signaling in Glioblastoma

  2016cites this paper
• Erratum to: Primary glioblastoma multiforme tumors and recurrence: comparative analysis of the danger signals HMGB1, HSP70, and calreticulin

  2016cites this paper
• Differential proteomics analysis of low- and high-grade of astrocytoma using iTRAQ quantification

  2016cites this paper
• Microsomal membrane proteome of low grade diffuse astrocytomas: Differentially expressed proteins and candidate surveillance biomarkers

  2016cites this paper
• Advances in Omics Technologies in GBM

  2015cites this paper
• Primary glioblastoma multiforme tumors and recurrence

  2015cites this paper
• Targeted Proteomics to Assess the Response to Anti-Angiogenic Treatment in Human Glioblastoma (GBM)*

  2015influential citation
• Transcriptomic and Proteomic Data Integration and Two-Dimensional Molecular Maps with Regulatory and Functional Linkages: Application to Cell Proliferation and Invasion Networks in Glioblastoma.

  2015cites this paper
• Physical characterization and profiling of airway epithelial derived exosomes using light scattering.

  2015cites this paper
• Bench to bedside: Still a pipedream?

  2015cites this paper
• Employment of Exosomes for Liquid Biopsies

  2015cites this paper
• Insights from Chromosome-Centric Mapping of Disease-Associated Genes: Chromosome 12 Perspective.

  2015cites this paper